Taysha Gene Therapies (TSHA) PT Raised to $47 at Needham & Company

October 5, 2021 2:05 PM EDT
Get Alerts TSHA Hot Sheet
Price: $12.54 --0%

Rating Summary:
    10 Buy, 1 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 5 | New: 8
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Needham & Company analyst Gil Blum raised the price target on Taysha Gene Therapies (NASDAQ: TSHA) to $47.00 (from $45.00) while maintaining a Buy rating.

The analyst commented, "Taysha announced the licensing of a clinical stage CLN7 gene therapy program from Steven Gray's lab at UTSW. A first iteration of this program is currently in the clinic and has been administered IT to two patients, one at 5X1014 vg and another at 1X1015 vg with an additional 2 patients planned for the highest dose. Preliminary results from the first patients are expected by YE:21. Taysha plans to advance a next-gen construct for CLN7 directly into a pivotal study in 2022. In its discussion with the FDA and ahead of this planned pivotal, Taysha intends to use additional preclinical results for the new construct to evaluate potential bridging strategies. We estimate potential sales reaching ~$300M by 2028 and are increasing our price target to $47."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Needham & Company, FDA